Tenax Therapeutics to Present Phase 3 LEVEL Trial Data at ESC Congress; Topline Results Expected August
TENX has more than doubled off its 52-week low of $5.66.
Summary
Tenax Therapeutics will present Phase 3 LEVEL clinical trial data at the European Society of Cardiology (ESC) Congress 2026, scheduled for August 28-31. The company anticipates reporting topline results for the registrational trial in August 2026. This update follows recent agreements for the long-term supply of its oral levosimendan product, the drug being evaluated in the LEVEL trial. The LEVEL trial addresses PH-HFpEF, a condition currently without approved treatments, making these results critical for the company's future. Topline data is expected in August, with the presentation at ESC Congress shortly thereafter.
At the time of this announcement, TENX was trading at $13.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $352.5M. The 52-week trading range was $5.66 to $18.38. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.